The effect of maternally transferred monoclonal antibody (MAb) on the offspring antibody response to rgp120 s F2 was examined in a murine model. Two MAbs were studied: MAb 83.1, which recognizes a determinant in the V3 loop of gp120 from human immunodeficiency virus-I (HIV-1) SF2, and MAb 26.2D3, which recognizes a conserved N-terminal region of gp120 from HIV-1 sF 2 • Offspring were immunized at 18-21 days of age with 100 p,g of rgp120 s F2 in complete Freund's adjuvant. Offspring immunized in the presence of preexisting MAb 83.1 but not MAb 26.2D3 demonstrated inhibition of the IgG anti-V3 response. The total IgG anti-rgp120 s F 2 response was not affected by preexisting MAb. Since newborns at risk for HIV may be immunized in the presence of maternal or administered anti-HIV antibody, alternative strategies may be required to circumvent inhibition of the infant's epitope-specific response to HIV immunization by preexisting antibody.
Many strategies are being evaluated to prevent transmission of human immunodeficiency virus (HIV) from an infected mother to her infant [I, 2] . The AIDS Clinical Trials Group (protocol 185) is currently evaluating the effect of HI V immune globulin on maternal transmission ofHIV. Ultimately, antibody may be combined with a successful vaccine.
We have developed the murine model for studying effects of preexisting antibody on the murine offspring response to candidate HIV vaccines. In our earlier experiments, we found that maternally transferred polyclonal antibody profoundly inhibited the offspring IgG response to an rgp 120 vaccine [3] .
In experiments presented here, we demonstrate the effect of maternally transferred monoclonal antibody (MAb) on the subsequent offspring total antibody response and the fine specificity of that response.
Methods

Mice
Specific pathogen-free adult BALB/c mice (Jackson Laboratory, Bar Harbor, ME) were bred for not more than three generations in our laboratory. All immunizations and antibody injections were administered intraperitoneally (ip). MAb was administered to postpartum mice within 24 h after birth of the offspring in a total volume of 0.5-1.0 mL. Antigens were administered in complete Freund's adjuvant (CFA; Life Technologies GIBCO BRL, Gaithersburg, MD) in a total volume of 0.1-0.2 mL. Mice were bled through the retroorbital sinus.
MAb Administered to Postpartum Mice
MAb 83.1 (lot A-2; Repligen, Cambridge, MA) is a BALB/c IgG I MAb that neutralizes HIV -1SF2 [4] . This MAb binds to a determinant defined by amino acids IXIGPGR of the V3 loop of HIV-l (X can be H, Y, T, R, N, S, or A). Antigens Administered to Offspring Mice rgp120 sF2 . Immunization was done ip with 100 J-lg of glycosylated recombinant gp 120 from HIV -1SF2 in CFA. This vaccine (lot P1.6-a) was prepared at Chiron in CHO cells [5] and is currently used in clinical trials.
Hen egg white lysozyme (HEL). HEL is a l29-amino acid protein antigen that we have previously studied in the murine system [6, 7] . Immunization was also done ip with 100 J-lg of HEL in CFA. HEL was obtained from Societa Prodotti Antibiotici (Milan, Italy).
Experimental Design
The purpose of these experiments was to determine if preexisting maternally transferred~Ab to the V3 loop of HIV-1SF2 would alter the magnitude and specificity of the offspring response to an rgpI20 sF2 vaccine. Three groups of offspring mice were studied: offspring of mice injected within 24 h postpartum with 500 J-lg of MAb 83.1, the anti -V3 loop MAb; offspring of mice injected postpartum with 500 J-lg of MAb 26.2D3, the control MAb; and control offspring of female mice without any antibody administered. All offspring mice were immunized ip at 18-21 days ofage with 100 J-lg of rgp 120 sF2 in CFA. Each group consisted of 3 postpartum mice and the offspring.
In additional experiments, the offspring of 1 postpartum mouse injected with MAb 83.1 and the offspring of a control postpartum mouse were immunized at 18-21 days of age with HEL in CFA to assess nonspecific effects on the response to an unrelated protein antigen. These offspring mice were also used to determine the half-life of transferred maternal antibody (MAb 83.1) in the sera of the offspring.
Antibody Assays
Anti-rgp120 sF2IgG ELISA and anti-HEL IgG ELISA. We have described these methods in our earlier work [3, 7] . After incubation of dilutions of mouse sera on either rgp 120 sFr or HEL-coated plates, alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotechnology, Birmingham, AL) was used for development with p-nitrophenyl phosphate as substrate. Each assay was standardized with a pooled polyclonal serum obtained from adult mice immunized with rgp 120 sF2 in CFA or HEL in CFA. Each immune serum was assigned a value of 10,000 arbitrary units/mL and was used to generate a standard curve.
Anti-Vi (anti-RP150) IgG ELISA. Plates were coated as described [3] with RPI50. This peptide represents the entire V3 loop of HIV-I sF2 and has the sequence NNTRKS.IYI..GPGRAFHTT-GRIIGC [4] . Alkaline phosphatase-conjugated goat anti-mouse IgG (Southern Biotechnology) was used for development with pnitrophenyl phosphate as substrate. A standard curve was generated with MAb 83.1 (lots A-2 or 6).
Statistical Analyses
Statistical analyses used the BMDP (Los Angeles, CA) statistical software program. Probability values were calculated with the Fisher's exact test and Student's t test.
Results
Anti-rgp120 sF2 IgG response. There was no effect ofpreexisting maternally transferred MAb on the total anti-rgp120 s F2 IgG response to immunization. The total serum IgG antibody response was determined for 9 weeks after immunization of the offspring mice at age 18-21 days (table 1). The geometric mean titer at each interval after immunization was similar for offspring with preexisting MAb 83.1 or preexisting MAb 26.2D3 or for mice without preexisting antibody.
At the time of immunization (day 0), the serum geometric mean concentration ofMAb 83.1 for offspring with preexisting MAb 83.1 was 8.1 j.lg/mL (95% confidence interval, 6.0-10.95 j.lg/mL). For offspring with preexisting MAb 26.2D3, the geometric mean concentration of 26.2D3 at the time of immunization was 2.84 j.lg/mL (95% confidence interval, 2.49-3.24 j.lgl mL). Thus, offspring with preexisting MAb 83.1 had '-""3-fo1d increased preexisting MAb compared with offspring with preexisting MAb 26.2D3 on day 0 when both were assayed using rgp120 sF2-coated ELISA plates.
Anti-V3 IgG antibody response. The fine specificity of the offspring vaccine response was altered by preexisting maternal MAb. Offspring mice, immunized in the presence of preexisting anti-V3 antibody, did not respond to the V3 epitope of rgp120 s F2 • The geometric mean titer of anti-V3 IgG antibody was significantly lower at both 42 days and 63 days after immunization when the MAb 83.1 (V3-loop) group was compared to the non-MAb control group (P < .001; table 2). Similarly, the geometric mean titer of anti-V3 loop IgG antibody was significantly lower at both 42 and 53 days after immunization when the V3-loop MAb group was compared to the control MAb group (P < .005 and P < .001).
The concentration of preexisting anti-V3 loop antibody was 13.2 j.lg/mL in the V3-loop MAb group and was not detected in the control non-MAb group or the control MAb group. There was no effect of preexisting MAb 26.2D3, the control MAb, on the anti-V3 component of the offspring response compared with that of controls, presumably since this Mab recognizes an N-terminal determinant of rgp120 s F2 , not in the V3 loop.
The absence of the anti-V3 component is more striking when the data are examined as the number of mice in each group with detectable anti-V3 loop antibody. At 9 weeks after immunization (age 12 weeks), 18 of 20 non-MAb control mice and There was no effect of preexisting maternally transferred MAb 83.1 on the offspring anti-HEL IgO response. Preexisting MAb 83.1 concentration was 7.8 j.lg/mL (95% confidence interval, 6.3-9.7 j.lg/mL) at the time of immunization. There was no preexisting anti-HEL antibody in these mice. This group of HEL-immunized offspring mice (n = 7) was also used to determine that the serum half-life for MAb 83.1 was 12.3 days between 3 and 12 weeks of age. There was a small amount of residual antibody even at 12 weeks of age (9 weeks after immunization).
Discussion
Our previous studies [3] have shown that maternal polyclonal antibody can profoundly suppress the murine offspring total IgO response to an rgp 120 s I-2 vaccine. The studies presented here with maternally transferred MAb did not demonstrate an inhibition of the total IgO anti-rgp l Zue-, response but rather a profound alteration of the fine specificity of that response. In these MAb studies, preexisting MAb to the V3 loop of HIV-1 prevented an anti -V3 loop IgO antibody response following immunization with rgp 120 5 1-2 . These results strongly support an epitope-blocking mechanism for the observed inhibition in both the previous polyclonal antibody and current MAb studies. If a more rapid clearance of antigen by preexisting antibody was the mechanism for the observed inhibition, the epitopespecific effect we observed would be very unlikely.
Many studies have examined the effects of preexisting antibody on the offspring response to immunization [8] [9] [10] [11] [12] . For the human infant, recent studies have demonstrated inhibitory effects of maternal antibody to tetanus toxoid [8] , antibody to diphtheria toxoid [9, 10] , and antibody to pertussis antigen [11] . Effects of maternal antibody on the murine offspring response to inactivated rabies virus vaccine have been studied by Xiang and Ertl [12] . Polyclonal maternal antibody from previously immunized mother mice inhibited the total antibody response of the offspring to vaccine as we also observed in our earlier studies [3] . These investigators also examined direct administration of a panel of MAbs. The fine specificity of the vaccine antibody response was examined, but no evidence of an epitope-specific inhibition was demonstrated. Our study demonstrating epitope-specific inhibition differed from the work of Xiang and Ertl [12] in that a single MAb was administered, not a panel of MAbs with different fine specificities. In addition to epitope masking, we have considered other mechanisms of inhibition, including altered presentation of peptides to T cells. Soluble antibody has been shown to block B cell presentation of antigen to a T cell clone [13] . We cannot exclude such a mechanism in our study. Our data also cannot exclude idiotypic network perturbation in neonatal mice [14] by maternal MAb since neonatal mice are very susceptible to exposure to immunoglobulin idiotypes in the first weeks of life. Since Fe-mediated inhibition of B cell responses is generally considered to be antigen-specific, not epitope-specific, it is an unlikely mechanism [15] .
Our data suggest that epitope blocking has occurred in which preexisting antibody to the V3 peptide prevented the recognition of this epitope by B cells. The studies of the catabolism of MAb 83.1 in the offspring found a serum half-life of 12.3 days, suggesting that the anti-V3 antibody present in only 2 offspring, 9 weeks after immunization, may have been residual maternal antibody. It is possible that none of the offspring responded to the V3 peptide.
Although our studies have examined epitope-specific effects of maternal antibody on the offspring response to vaccine antigen, it is also possible that the specificity of the immune response to natural infection with HIV -1 could be altered by antibody. Such effects may be the result of maternal antibody or administered neutralizing antibody during pregnancy or at delivery. Altered specificity of the immune response to infection could potentially enhance the pathogenesis of HIV infection in the infant.
In summary, we have demonstrated that preexisting maternal anti-V3 MAb, a neutralizing MAb for HIV-l, profoundly altered the fine specificity of the offspring response to an rgp 120 s F2 vaccine. Antibody to a neutralizing determinant, the V3 loop, was missing from the response. Such studies clearly demonstrate that preexisting antibody, either exogenously administered directly to the infant or transferred to the infant from the mother, may alter the vaccine response. HIV vaccines that are successful in adults and older infants may not be successful in the newborn. Alternative immunization strategies may be necessary to overcome inhibition by maternal antibody in the newborn.
